Security key
816212302
Cartesian Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RNAC)
CUSIP: 816212302
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 5,968,086
- Total 13F value
- $60,898,831
- Share change
- -433,710
- Put/Call ratio
- 20%
- SEC-reported price per share
- $10.22
- Number of holders
- 65
- Value change
- -$4,440,064
- Number of buys
- 26
- Number of sells
- 24
- Shares outstanding
- 30,963,583
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
65
Top holders
10
RNAC full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Cartesian Therapeutics, Inc. SEC filings
Cartesian Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 816212302
Recent filing periods:
Ownership snapshot
Top reported holders of RNAC - Cartesian Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Timothy A. Springer
Disclosed value leader
Timothy A. Springer
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
Lead comparable stake: 37%
13D/G row: Timothy A. Springer
Showing 1-6 of 15 holder rows.
Quick read
Timothy A. Springer leads the comparable SEC ownership view at 37%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Timothy A. Springer's linked filing trail.
Comparable ownership
Top 5
Timothy A. Springer
37%
FMR LLC
7.5%
MPM BioImpact LLC
2.2%
BlackRock, Inc.
2.1%
Siren, L.L.C.
1.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Timothy A. Springer |
13D/G
|
37%
|
$116,671,361
9,555,394 shares
|
+$258,583 | 13 Jan 2025 |
| FMR LLC |
13F
Company
|
7.5%
|
$24,251,549
2,334,124 shares
|
— | 30 Jun 2025 |
| MPM BioImpact LLC |
13F
Company
|
2.2%
|
$7,127,613
686,007 shares
|
— | 30 Jun 2025 |
| BlackRock, Inc. |
13F
Company
|
2.1%
|
$6,793,398
653,840 shares
|
— | 30 Jun 2025 |
| Siren, L.L.C. |
13F
Individual
|
1.8%
|
$5,852,396
563,272 shares
|
— | 30 Jun 2025 |
| VANGUARD GROUP INC |
13F
Company
|
1.6%
|
$5,157,243
496,366 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
65
Shares
5,968,086
Rows available
65
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
65
Q3 2025 holders
65
Holder diff
0
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend